JP2019526543A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526543A5
JP2019526543A5 JP2019506143A JP2019506143A JP2019526543A5 JP 2019526543 A5 JP2019526543 A5 JP 2019526543A5 JP 2019506143 A JP2019506143 A JP 2019506143A JP 2019506143 A JP2019506143 A JP 2019506143A JP 2019526543 A5 JP2019526543 A5 JP 2019526543A5
Authority
JP
Japan
Prior art keywords
agent
cancer
antigen
patient
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019506143A
Other languages
English (en)
Japanese (ja)
Other versions
JP7158372B2 (ja
JP2019526543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/045643 external-priority patent/WO2018027205A1/en
Publication of JP2019526543A publication Critical patent/JP2019526543A/ja
Publication of JP2019526543A5 publication Critical patent/JP2019526543A5/ja
Priority to JP2022131006A priority Critical patent/JP2022161992A/ja
Application granted granted Critical
Publication of JP7158372B2 publication Critical patent/JP7158372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019506143A 2016-08-05 2017-08-04 癌治療のための修飾抗体-アルブミンナノ粒子複合体 Active JP7158372B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022131006A JP2022161992A (ja) 2016-08-05 2022-08-19 癌治療のための修飾抗体-アルブミンナノ粒子複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662371668P 2016-08-05 2016-08-05
US62/371,668 2016-08-05
US201662409830P 2016-10-18 2016-10-18
US62/409,830 2016-10-18
PCT/US2017/045643 WO2018027205A1 (en) 2016-08-05 2017-08-04 Modified antibody-albumin nanoparticle complexes for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022131006A Division JP2022161992A (ja) 2016-08-05 2022-08-19 癌治療のための修飾抗体-アルブミンナノ粒子複合体

Publications (3)

Publication Number Publication Date
JP2019526543A JP2019526543A (ja) 2019-09-19
JP2019526543A5 true JP2019526543A5 (enExample) 2020-09-17
JP7158372B2 JP7158372B2 (ja) 2022-10-21

Family

ID=59677326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019506143A Active JP7158372B2 (ja) 2016-08-05 2017-08-04 癌治療のための修飾抗体-アルブミンナノ粒子複合体
JP2022131006A Pending JP2022161992A (ja) 2016-08-05 2022-08-19 癌治療のための修飾抗体-アルブミンナノ粒子複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022131006A Pending JP2022161992A (ja) 2016-08-05 2022-08-19 癌治療のための修飾抗体-アルブミンナノ粒子複合体

Country Status (11)

Country Link
US (2) US20210267930A1 (enExample)
EP (1) EP3493854B1 (enExample)
JP (2) JP7158372B2 (enExample)
KR (2) KR20230006037A (enExample)
CN (1) CN109922836A (enExample)
AU (1) AU2017307618A1 (enExample)
CA (1) CA3032947A1 (enExample)
IL (1) IL264598A (enExample)
MX (1) MX2019001517A (enExample)
RU (1) RU2019105550A (enExample)
WO (1) WO2018027205A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
WO2015195476A1 (en) 2014-06-16 2015-12-23 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research T細胞癌を標的とする為の方法及び組成物
MX2019002474A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
US11531030B2 (en) 2017-04-21 2022-12-20 Mayo Foundation For Medical Education And Research Polypeptide-antibody complexes and uses thereof
US20210023233A1 (en) * 2018-02-06 2021-01-28 Mayo Foundation For Medical Education And Research Antibody-peptide complexes and uses thereof
JP7308507B2 (ja) * 2019-01-31 2023-07-14 Spiber株式会社 組換え構造タンパク質の製造方法及び分析方法、並びにタンパク質成形体の製造方法
CN116687833A (zh) * 2023-07-24 2023-09-05 中山大学 一种含有抗体偶联白蛋白紫杉醇纳米药物的可溶性微针及其制备方法和应用
CN119405830B (zh) * 2024-09-19 2025-09-05 北京大学 一种纳米抗体偶联物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN1980699B (zh) * 2004-05-14 2012-03-21 阿布拉西斯生物科学公司 利用白蛋白-结合蛋白作为靶标的治疗方法
EP1799713B1 (en) * 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2009322126B2 (en) * 2008-12-05 2013-06-20 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
CN102458471A (zh) * 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
EP2903610B1 (en) * 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
ES2763318T3 (es) * 2014-10-06 2020-05-28 Mayo Found Medical Education & Res Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CA3080406A1 (en) * 2016-10-28 2018-05-03 Nrl Pharma, Inc. Lactoferrin/albumin fusion protein and production method thereof

Similar Documents

Publication Publication Date Title
JP2019526543A5 (enExample)
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2023014569A (es) Anticuerpos anti-sirpa.
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
JP2018012698A5 (enExample)
JP2015503422A5 (enExample)
MX392779B (es) Anticuerpos anti-cd27
JP2014530840A5 (enExample)
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
JP2016540026A5 (enExample)
JP2016540019A5 (enExample)
JP2015173751A5 (enExample)
IL269769B (en) Compounds, composition and uses thereof for treating cancer
JP2017516883A5 (enExample)
JP2019526545A5 (enExample)
WO2016057726A3 (en) Human anti-vegfr-2/kdr antibodies
CN302548735S (zh) 酱料瓶
CN302591127S (zh) 光子嫩肤机(Mask-Ⅱ)
JP2019074725A5 (enExample)
CN302465229S (zh) 酱料挤压瓶
CN302554027S (zh) 抽屉照明器
CN302509246S (zh) 开罐器(1021)
CN302509247S (zh) 开罐器(1022)
CN302487713S (zh) 开罐器(1020)
CN302421199S (zh) 铰链